Skip to content

Released Aug 11, 2025, before the open

10-Q filed Aug 11, 2025, 42 days after period end · 0001171843-25-005261

Q2 2025 · 10-Q
Revenue$0.00−100.0% vs Q2 2024no prior Q1 2025 on file
Net Income-$19.88MN/M vs Q2 2024N/M vs Q1 2025
EPS, diluted—
Operating Income-$21,066,000N/M
Operating Cash Flowderived-$11,832,000N/M
Free Cash Flowderived-$11,832,000N/M

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$0.00$850.00K$0.00—
Net Income-$19.88M-$13.08M-$11.28M-$8.49M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR